CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile

Submitted by Anonymous (not verified) on
Code
MOG-CTIP-01AX
Test
Active-Compendium
81540 for CancerTYPE ID. Add CPT Codes for the specific NeoTYPE Cancer Profile performed.
Clinical
Oncology,Pathology
FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixative.
Solid Tumors
Adrenal gland
Biliary tract
Bladder
Breast
Central nervous system (CNS)
Cervix
Colorectal
Endometrium
Gastroesophageal
GIST/Soft Tissue
Kidney
Liver
Lung
Melanoma/Skin
Ovary
Pancreas
Prostate
Salivary Gland
Thyroid
Upper Aerodigestive tract
Next Generation Sequencing (NGS)
Global
Flag Active
True
Orderable Test Description
<p data-prosemirror-content-type="node" data-prosemirror-node-name="paragraph" data-prosemirror-node-block="true" data-pm-slice="1 1 []">NeoGenomics has partnered with Biotheranostics, Inc., a Hologic Company, to make ordering&nbsp; CancerTYPE ID easy. CancerTYPE ID is a proprietary molecular cancer classifier used to identify unknown or unclear tumor types and subtypes in patients with metastatic cancer. The test uses quantitative RT-PCR to measure the expression of 92 genes in the patients specimen and classifies the tumor by matching the gene expression profile to a database of more than 2000 known tumor types and subtypes. Using this technology, CancerTYPE ID can identify 50 different tumor types and subtypes, covering &gt;95% of all solid tumors based on incidence. The test reports a main cancer type with the highest probability, as well as a list of tumor types that may be ruled out with 95% confidence.</p>
<p data-prosemirror-content-type="node" data-prosemirror-node-name="paragraph" data-prosemirror-node-block="true">When ordered through NeoGenomics, classification with CancerTYPE ID is followed by tumor profiling for actionable biomarkers using a NeoGenomics NGS Profile most appropriate for the tumor type identified by Cancer TYPE ID.</p>
<p data-prosemirror-content-type="node" data-prosemirror-node-name="paragraph" data-prosemirror-node-block="true">CancerTYPE ID may be ordered as a stand-alone test directly from Biotheranostics, Inc., a Hologic Company. Please see <a href="http://www.cancertypeid.com/" target="_blank" rel="noopener" data-prosemirror-content-type="mark" data-prosemirror-mark-name="link"><strong data-prosemirror-content-type="mark" data-prosemirror-mark-name="strong">http://www.cancertypeid.com</strong></a>.&nbsp;</p>
<p data-prosemirror-content-type="node" data-prosemirror-node-name="paragraph" data-prosemirror-node-block="true">CancerTYPE ID is performed, reported, and billed separately by Biotheranostics, Inc., a Hologic Company, an independent CLIA-licensed and CAP-accredited reference laboratory.&nbsp;</p>
Orderable Turn Around Time
Approximately 21-23 days. CancerTYPE ID results can be expected 7-9 calendar days after receipt of specimen and required information into Biotheranostics’ laboratory. NeoTYPE Cancer Profile results follow approximately 14 days later.
Keywords
CTID
Biotheranostics
TUO
CUP
Cancer Type ID
CancerTYPEID
Cancer TYPEID
uncertain primary
unknown primary
unknown origin
unclear origin
unclear diagnosis
Meta Description
CancerTYPE ID followed by NeoTYPE Cancer Profile provides molecular classification of unknown or unclear tumor types and profiling for actionable biomarkers most relevant in the tumor type identified.
Extra Note

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.

NY Approved
True
Keywords string
CTID, Biotheranostics, TUO, CUP, Cancer Type ID, CancerTYPEID, Cancer TYPEID, uncertain primary, unknown primary, unknown origin, unclear origin, unclear diagnosis CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile
Title URL
cancertype-id-with-reflex-to-neotype-cancer-profile